OBJECTIVE： To systematically review the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of the non-small cell lung cancer （NSCLC）， and provide evidence-based reference for clinical treatment. METHODS： Retrieved from PubMed， Cochrane Library， EMBase， VIP， CJFD，Wanfang database and CBM， randomized controlled trials （RCT） about the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of NSCLC were collected. Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation with modified Jadad scale. RESULTS： Totally 9 RCTs were included， involving 561 patients. Results of Meta-analysis showed， Kanglaite injection combined with radiothreapy can significantly improve the effective rate [OR＝2.99，95％CI（2.07，4.31），P＜0.001] and improvement rate of life quality [OR＝3.74，95％CI（2.36，5.92），P＜0.001]， and reduce the incidence of radiation pneumonitis [OR＝0.23，95％CI（0.12，0.47），P＜0.001] and radiation esophagitis [OR＝0.10，95％CI（0.05，0.21），P＜0.001] of NSCLC patients， the differences were statistically significant. CONCLUSIONS： Both the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of NSCLC are superior to radiothreapy alone.